Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM NITROPRUSSIDE vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium nitroprusside is a prodrug that releases nitric oxide (NO) in vascular smooth muscle cells, activating guanylate cyclase and increasing c GMP, leading to vasodilation of both arterial and venous vessels.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Immediate reduction of blood pressure in hypertensive crises,Induction of controlled hypotension during anesthesia,Treatment of acute heart failure (off-label)
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Intravenous infusion: Initial 0.3-0.5 mcg/kg/min; titrate up to 10 mcg/kg/min, maximum 10 mcg/kg/min for up to 10 minutes. Usual therapeutic dose: 3 mcg/kg/min. Max cumulative dose: 3.5 mg/kg.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Sodium nitroprusside itself has a half-life of approximately 2 minutes (converted to cyanide in erythrocytes); the metabolite thiocyanate has a terminal half-life of 2.7-7 days (prolonged in renal impairment, requiring monitoring)
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Sodium nitroprusside undergoes non-enzymatic degradation in erythrocytes and tissues, releasing cyanide. Cyanide is metabolized by rhodanese (thiosulfate sulfurtransferase) to thiocyanate, primarily in the liver and kidneys.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal: approximately 75% as thiocyanate (metabolite) with 25% unchanged; biliary/fecal: minimal (<5%)
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Sodium nitroprusside: negligible protein binding (<5%); thiocyanate: weakly bound to plasma proteins (approximately 5%)
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Sodium nitroprusside: approximately 0.2 L/kg (distributes primarily in extracellular fluid); thiocyanate: approximately 0.2-0.3 L/kg (distributes similarly to extracellular water)
4-6 L/kg; large Vd indicates extensive tissue distribution
Intravenous: 100% (only route of administration); oral: not applicable (no oral bioavailability due to instability and extensive first-pass metabolism)
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
GFR <60 m L/min: Use with caution; reduce initial dose by 50% and monitor for cyanide toxicity. GFR <30 m L/min: Avoid due to risk of thiocyanate accumulation.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh Class B: Reduce initial dose by 50% and monitor for cyanide toxicity; maximum infusion rate 2 mcg/kg/min. Child-Pugh Class C: Contraindicated due to risk of severe cyanide toxicity.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Children: Intravenous infusion 0.3-1 mcg/kg/min initially; titrate to effect, not to exceed 10 mcg/kg/min. Neonates: 0.5-1 mcg/kg/min; maximum 5 mcg/kg/min.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Elderly: Lower initial doses (0.3-0.5 mcg/kg/min) with slower titration; increased sensitivity to hypotension. Monitor for thiocyanate accumulation (normal renal function may decline with age).
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Sodium nitroprusside can cause excessive hypotension and cyanide toxicity. Continuous monitoring of blood pressure and cyanide/thiocyanate levels is required. Prolonged infusion or high doses increase risk of cyanide poisoning.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Risk of cyanide toxicity, especially with prolonged infusion or renal impairment,Thiocyanate toxicity with renal failure,Hypotension requiring continuous blood pressure monitoring,Methemoglobinemia (rare)
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Pre-existing hypotension,Compensatory hypertension (e.g., coarctation of aorta),Leber's optic atrophy (cytochrome oxidase deficiency),Severe renal impairment,Congenital optic atrophy,Poorly compensated heart failure
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
No specific food interactions. Patients should avoid excessive vitamin B12 or sulfur-containing supplements due to theoretical risk of increased thiocyanate production.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Pregnancy Category C. Risk cannot be ruled out. Animal reproduction studies have not been conducted with sodium nitroprusside. It should only be used in pregnant women if the potential benefit justifies the potential risk to the fetus. Due to its vasodilatory effects and potential for maternal hypotension, fetal hypoxia may occur. Use during labor may cause uterine relaxation and prolonged labor.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
It is unknown if sodium nitroprusside is excreted in human breast milk. The M/P ratio is not available. Due to the short half-life and rapid metabolism, exposure to the nursing infant is likely minimal, but caution is advised.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No specific dose adjustments are recommended based solely on pregnancy. However, due to increased plasma volume and cardiac output during pregnancy, the hemodynamic response may be altered. Start at the low end of the dosing range (0.3-0.5 mcg/kg/min) and titrate to effect. Shorter duration of therapy is advised to minimize the risk of cyanide accumulation.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Protect solution from light; wrap infusion set with opaque material. Use only in ICU setting with continuous blood pressure monitoring. Monitor for cyanide toxicity, especially with high doses (>2 mcg/kg/min) or renal impairment. Onset of action is immediate; titrate to effect every 5 minutes. Do not use for more than 48 hours to avoid thiocyanate accumulation. Administer via dedicated IV line; incompatible with many drugs.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
This medication is used to rapidly lower blood pressure in emergencies.,You will have continuous blood pressure monitoring; report any headache, dizziness, nausea, or palpitations.,The solution is light-sensitive; the IV bag and tubing are wrapped to protect it.,Inform your doctor if you have kidney or liver disease, or a history of cyanide poisoning.,Do not stop the infusion abruptly; blood pressure must be reduced gradually.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
"Primidone, a barbiturate anticonvulsant, can potentiate the hypotensive effects of sodium nitroprusside, a direct vasodilator used in hypertensive emergencies. This interaction may lead to exaggerated reductions in blood pressure, increasing the risk of hypotension, syncope, and reflex tachycardia. Such additive hypotensive effects necessitate careful monitoring and dose adjustments to prevent adverse cardiovascular outcomes."
"Amlodipine, a dihydropyridine calcium channel blocker, causes peripheral vasodilation by inhibiting calcium influx into vascular smooth muscle cells. Nitroprusside, a direct vasodilator, releases nitric oxide which activates guanylyl cyclase, leading to increased cGMP and smooth muscle relaxation. Concomitant use can lead to additive hypotension, potentially resulting in dizziness, syncope, or cardiovascular collapse, especially in patients with compromised cardiac function or volume depletion."
"Concurrent use of nitroprusside and diclofenamide may lead to an exaggerated hypotensive response. Diclofenamide, a carbonic anhydrase inhibitor, can cause metabolic acidosis and electrolyte disturbances, which may potentiate the vasodilatory effects of nitroprusside, increasing the risk of severe hypotension and reflex tachycardia. This interaction is particularly hazardous in patients with compromised cerebral or coronary perfusion, as it may precipitate ischemic events."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM NITROPRUSSIDE vs ABSTRAL, answered by our medical review team.
SODIUM NITROPRUSSIDE is a Vasodilator that works by Sodium nitroprusside is a prodrug that releases nitric oxide (NO) in vascular smooth muscle cells, activating guanylate cyclase and increasing c GMP, leading to vasodilation of both arterial and venous vessels.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM NITROPRUSSIDE and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM NITROPRUSSIDE is: Intravenous infusion: Initial 0.3-0.5 mcg/kg/min; titrate up to 10 mcg/kg/min, maximum 10 mcg/kg/min for up to 10 minutes. Usual therapeutic dose: 3 mcg/kg/min. Max cumulative dose: 3.5 mg/kg.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM NITROPRUSSIDE and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM NITROPRUSSIDE is classified as Category C. Pregnancy Category C. Risk cannot be ruled out. Animal reproduction studies have not been conducted with sodium nitroprusside. It should only be used in pregnant women if the poten. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.